High endothelial venules (HEVs) are structurally distinct blood vessels that develop during embryonic and neonatal life in all secondary lymphoid organs except the spleen. HEVs are critical for initiating and maintaining immune responses because they extract naïve and memory lymphocytes from the bloodstream, regardless of antigen receptor specificity, and deliver them to antigen-presenting cells inside lymph nodes under homeostatic conditions. HEVs also develop post-natally in nonlymphoid organs during chronic inflammation driven by autoimmunity, infection, allografts and cancer. Extranodal HEVs are usually surrounded by dense lymphocytic infiltrates organised into lymph-node like, T-and B-cell rich areas called tertiary lymphoid structures (TLS). HEV neogenesis is thought to facilitate the generation of tissue-destroying lymphocytes inside chronically inflamed tissues and cancers.
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We are studying the mechanisms underpinning HEV neogenesis in solid cancers and the role of homeostatic T cell trafficking in controlling cancer immunity. In this chapter we describe methods for identifying HEV in tissue sections of cancerous tissues in humans and mice using immunohistochemical staining for the HEVspecific marker peripheral lymph node addressin (PNAd). L-selectin binding to PNAd is a necessary first step in homeostatic lymphocyte trafficking which is the defining function of HEV. We also describe methods to measure L-selectin dependent homing of lymphocytes from the bloodstream into lymphoid tissues and tumours in preclinical cancer models.
Introduction
High endothelial venules (HEVs) are structurally and antigenically distinct blood vessels especially adapted for lymphocyte trafficking (1). HEV develop in every secondary lymphoid organ except the spleen (i.e. lymph nodes (LN), tonsils and Here, lymphocytes scan dendritic cells and stromal networks for activating, tolerogenic and homeostatic stimuli. HEV, therefore, regulate the outcome of an immune response be it activation, tolerance or homeostatic proliferation of lymphocytes. PNAd-expressing blood vessels that resemble structurally distinct HEV in LN, develop post-natally in non-lymphoid organs during chronic inflammation driven by autoimmunity, infection and allografts (6) . These extranodal HEV are characteristically surrounded by dense lymphocytic infiltrates organised into lymphnode like structures with discrete T and B-cell rich areas and germinal centres and are called tertiary lymphoid structures (TLS). Extranodal HEV facilitate entry of blood borne lymphocytes and are therefore, critical to the development and immune function of TLS. HEV-containing TLS also develop in solid, vascularised cancers and are receiving increasing attention because of their potential role in regulating immunity at the tumor site (7, 8) . The presence of TLS in resected solid cancers has been correlated with prolonged patient outcome in some cancers such as breast cancer (9, 10), melanoma (11, 12) and lung cancer (13). In other cancers, TLS have been shown to either promote carcinogenesis such as virus-associated hepatocellular carcinoma (14) , or to accumulate with disease progression such as in primary breast carcinoma (15) . In colorectal cancer, TLS often containing germinal centres (Crohn's-like aggregates), develop in the surrounding peritumoural stroma as well as inside cancerous tissue. The number of TLS in colorectal cancer has been reported to correlate either with improved patient outcome or with disease progression depending on the stage of the disease (16-19).
In breast cancer and melanoma, the density of HEV correlated with improved patient outcome highlighting the important role that HEV play in orchestrating anti-cancer immunity (20, 21) . HEV neogenesis correlates with regression of established tumours in preclinical mouse tumour immunotherapy models, such as depletion of
Foxp3
+ regulatory T cells (22, 23) or combined checkpoint blockade inhibition and angiogenesis therapy (24) . HEV neogenesis and tumour regression are also seen when the TNF superfamily member LIGHT (TNSF14) (which signals via LTβR, an important driver of lymphoid organ development) is expressed by tumour cells or targeted to tumours or tumour blood vessels (25) (26) (27) . It is thought that the anti- 
Materials
All reagents which are not commercially available should be prepared with 3. Dry ice with or without ethanol for snap freezing murine tissue in OCT.
4. Cryostat capable of cutting cryosections.
5. Hydrophobic pen for creating a hydrophobic barrier around tissue section (e.g.
Pap pen, Vector).
6. Humidified chamber containing wet paper towel to prevent evaporation of staining reagents.
7. PBS for washing steps. Mix the following to create a buffered lysine solution: 0.36g Lysine (Sigma), 7.5 mL NaH2PO4 (0.1M, pH 7.2; Sigma), 2.5 mL Na2HPO4
(0.1M, pH 7.2; Sigma) and 10 mL H2O. Immediately before use, add 15 mL of the buffered lysine solution to the following: 5 mL 8%
formaldehyde and 50 mg Sodium meta-periodate (NaIO4; Sigma). It is not necessary to pH the final solution.
9. If using formaldehyde or PLP to fix sections then prepare 0.3 M glycine (Thermo Fisher Scientific) in PBS, pH 7.4, to quench free aldehydes.
10. Optional: Avidin/Biotin blocking kit if a biotinylated primary or secondary antibody is used.
11. Serum blocking solution to block non-specific binding of antibodies. 2.5-5% serum of the species in which the secondary antibody is raised is often used.
Other sera, for example horse or mouse serum,may also be used. rabbit anti-human CD3, which also detects mouse CD3, DAKO A0452, used at 2 g/mL), B cells (biotinylated rat anti-mouse/human CD45R/B220, clone RA3-6B2, rat IgG2a, used at a working concentration of 2 g/mL, Biolegend), and FDC (rat anti-mouse FDC, clone FDC-M1, rat IgG2c, used at a working concentration of 2 g/mL, BD Biosciences).
13. For every antibody used, an isotype control antibody should be used at the same working concentration, in parallel on another section to check the staining is specific. A rat IgM isotype control antibody is used to check MECA-79 staining is specific. Biotinylated rat IgG2a is used to check pan-EC antigen (clone MECA-32), MAdCAM-1 (clone MECA-367) and B cell (clone RA3-6B2)
staining is specific (Figure 1) . Rat IgG2c is used to check FDC (clone FDC-M1) staining is specific and rabbit IgG polyclonal isotype control is used to check CD3 (DAKO A0452) staining is specific. 17. Glass coverslips (thickness #1.5 coverslips should be used in fluorescence microscopy to obtain the brightest images with minimal spherical aberration;
Thermo Fisher Scientific).
2 Immunolabelling HEV and TLS in paraffin-embedded murine tumour sections
1. Tissue-Tek plastic base molds (Thermo Fisher Scientific).
Neutral buffered formal saline (NBFS).
3. Paraffin wax (Shandon Histoplast, Thermo Fisher Scientific).
4. Microtome capable of cutting paraffin sections (e.g.Thermo Fisher Scientific).
5. Blades (MX35, Thermo Fisher Scientific).
6. Hydrophobic pen for creating a hydrophobic barrier around tissue section (e.g.Pap pen, Vector).
7. Humidified chamber containing wet paper towel to prevent evaporation of staining reagents.
8. 100% Xylene.
9. Graded alcohols: 100%, 95%, 90%, 80% and 70% ethanol.
10. PBS for washing steps.
11. Peroxidase blocking solution: either 1% hydrogen peroxide/methanol or a commercial blocking reagent (e.g. Bloxall; Vector) (see Note7).
12. Serum blocking solution to block non-specific binding of antibodies. Often 2.5-5% serum of the species in which the secondary antibody is made is used.
Other sera for example horse or mouse serum may also be used. 6. Red blood cell lysis buffer.
7. Naïve T cell isolation kits using negative selection. 9. Wash slides 3 times in PBS over 5 minutes.
10. Drain slides and carefully wipe off excess water before next step. Be carefully not to let the section dry out.
11. Draw a circle round each section with a hydrophobic marker.
12. Neutralize endogenous peroxidase activity with 1% hydrogen peroxide/ methanol for 10 min at RT or alternatively use a commercial blocking reagent (e.g.Bloxall, Vector; see Note 7).
13. Wash slides 3 times in PBS over 5 minutes.
14. Block non-specific protein binding with blocking solution for 30 min at RT. 2. Place cell strainer in neck of a labelled 50 mL polypropylene tube in a tube rack and pour spleen and PBS through cell strainer.
Drain slides (no need to wash
3. Split open paper covering of 2 mL plastic syringe, remove plunger using paper covering to maintain sterility of flat end (not rubber seal end). Mash spleen using flat end of plunger. Wash strainer using 5 mL of PBS, repeat if necessary to completely disaggregate tissue; discard strainer. 12. Lyse red blood cells in spleen, tumour and peripheral blood, as described in
Step 5. 14. Cryostat sections of 8 µm are cut from fixed, frozen tissues (see Step 11), HEV stained using MECA-79 and red fluorescence-conjugated secondary antibody, as described in Section 3.1, Step 12 but without additional fixation.
The presence of TLS in fixed tumour tissue may be revealed using antibodies that detect T and B cells in formalin-fixed paraffin embedded tissues ( Table   1 ). The position of CFSE-labeled lymphocytes (green) in relation to HEVs 
